title: Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.
abstract: OBJECTIVE
  This prospective study of patients treated at the Royal Marsden Hospital Lymphoma Unit was designed to evaluate the role of magnetic resonance imaging (MRI) in the assessment of residual masses evident on computed tomographic (CT) scanning following treatment of lymphoma.
  
  
  METHODS
  All patients had MRI, gallium-67 single-photon emission CT (67Ga SPECT), and erythrocyte sedimentation rate (ESR) performed within 3 months of completing therapy. Patients were monitored for 1 year posttreatment and observed for signs of relapse. Investigation results were correlated with disease status, and the sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) calculated. Time-to-relapse curves were derived and the log-rank test used to determine whether patients with a positive result were more likely to have a relapse within the mass than those with a negative result.
  
  
  RESULTS
  Thirty-four patients were studied, 14 of whom relapsed, 11 within the area of residual mass. Overall, MRI had a high specificity (90%), PPV (71%), and NPV (75%), but poor sensitivity (45%). The results for 67Ga SPECT were similar, apart from lower sensitivity (33%). ESR had inferior performance in predicting relapse compared with the other tests. MRI was the only investigation to show statistical significance (P = .14) in predicting relapse, and this was particularly evident in Hodgkin's lymphoma (P = .003). Combining results of 67Ga SPECT and MRI did not improve predictive power.
  
  
  CONCLUSIONS
  These data demonstrate that MRI is a valuable tool in the setting of a residual mass after treatment, giving clinically useful prognostic information. 67Ga SPECT also has a role, but is less effective in predicting relapse than MRI.
authors.affiliation: Cancer Research Campaign Section of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom.
authors.forename: M
authors.initials: M
authors.lastname: Hill
authors.forename: D
authors.initials: D
authors.lastname: Cunningham
authors.forename: D
authors.initials: D
authors.lastname: MacVicar
authors.forename: A
authors.initials: A
authors.lastname: Roldan
authors.forename: J
authors.initials: J
authors.lastname: Husband
authors.forename: R
authors.initials: R
authors.lastname: McCready
authors.forename: J
authors.initials: J
authors.lastname: Mansi
authors.forename: S
authors.initials: S
authors.lastname: Milan
authors.forename: T
authors.initials: T
authors.lastname: Hickish
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D001799:Blood Sedimentation; D005260:Female; D005710:Gallium Radioisotopes; D006801:Humans; D008223:Lymphoma / Q000097:blood / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000628:therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis* / Q000000981:diagnostic imaging; D011237:Predictive Value of Tests; D011336:Probability; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D005710:Gallium Radioisotopes